Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Moodys
Healthtrust
Colorcon
Medtronic
QuintilesIMS
Harvard Business School
Chubb

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,426,586

« Back to Dashboard

Which drugs does patent 8,426,586 protect, and when does it expire?

Patent 8,426,586 protects GILOTRIF and is included in one NDA.

This patent has fifty-eight patent family members in thirty-three countries.
Summary for Patent: 8,426,586
Title:Process for preparing amino crotonyl compounds
Abstract: An improved process for preparing 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline and related aminocrotonyl compounds and the preparation of a suitable salt of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-bute- n-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline for use as a pharmaceutically active substance.
Inventor(s): Soyka; Rainer (Biberach, DE), Rall; Werner (Mittelbiberach, DE), Schnaubelt; Juergen (Oberhoefen/Warthausen, DE), Sieger; Peter (Mittelbiberach, DE), Kulinna; Christian (Attenweiler, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:11/457,622
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,426,586
Patent Claim Types:
see list of patent claims
Compound; Process;

Drugs Protected by US Patent 8,426,586

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-001 Jul 12, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-002 Jul 12, 2013 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-003 Jul 12, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,426,586

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 49 113Oct 17, 2003

International Family Members for US Patent 8,426,586

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 2508521 ➤ Try a Free Trial
Slovenia 1678165 ➤ Try a Free Trial
Singapore 139743 ➤ Try a Free Trial
Serbia 20130524 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Fish and Richardson
US Army
Argus Health
Express Scripts
Teva
Healthtrust
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.